Clinical trials: Bone Marrow
Multiple Myeloma
A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma
This open-label study will assess anti-tumor activity and safety of belinostat in combination with bortezomib (Velcade®) in multiple myeloma patients refractory to or relapsed from at least one prior bortezomib-containing…
- Trial name
- NCT00431340
- Testing
- PXD101
- Where
- 3 sites in United States
- Volunteers
- 4 people
- Sponsor
- Valerio Therapeutics
Coronavirus Disease 2019 (COVID-19)
Bone Marrow-Derived Mesenchymal Stem Cell Treatment for Severe Patients With Coronavirus Disease 2019 (COVID-19)
Coronavirus Disease 2019 (COVID-19) is spreading worldwide and has become a public health emergency of major international concern. Currently, no specific drugs or vaccines are available.
- Trial name
- NCT04346368
- Testing
- BM-MSCs
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Guangzhou Institute of Respiratory Disease
Rheologic Disease, Sickle Cell Disease
Microvascular and Cardiac Dysfunction in Paroxysmal Nocturnal Hemoglobinuria and Sickle Cell Disease
The purpose of this study is to examine how abnormal blood flow in the small vessels (microvessels) of the heart, muscle and kidney in paroxysmal nocturnal hemoglobinuria (PNH) or sickle cell disease leads to poor functioning of…
- Conditions
- Rheologic Disease, Sickle Cell Disease, Paroxysmal Nocturnal Hemoglobinuria
- Trial name
- NCT01294891
- Testing
- Imaging
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Oregon Health and Science University
Hematology, MDS
Evaluating the Safety of Long Term Dosing of Romiplostim (Formerly AMG 531) in Thrombocytopenic Subjects With Myelodysplastic Syndromes (MDS)
This is an open label extension study of romiplostim for treatment of thrombocytopenia (platelet count ≤ 50 x 10^9/L) in MDS subjects.
- Conditions
- Hematology, MDS, Myelodysplastic Syndromes, Thrombocytopenia
- Trial name
- NCT00472290
- Testing
- Romiplostim (formerly AMG 531)
- Volunteers
- 72 people
- Sponsor
- Amgen
Paroxysmal Nocturnal Hemoglobinuria
NIS PDC the Efficacy and Safety of Iptacopan in Adults in Routine Clinical Practice
This is a prospective, non-interventional, multicenter study to evaluate the efficacy and safety of iptacopan in patients with PNH in real-world settings in Russia.
- Trial name
- PRIORITY- PNH (NCT07036718)
- Where
- 5 sites in Russia
- Volunteers
- 6 people
- Sponsor
- Novartis Pharmaceuticals
Blood Disease, Anemia, Aplastic
Aplastic Anemia Epidemiology: Incidence and Case-control
To conduct incidence and case-control studies of aplastic anemia in metropolitan Bangkok, Thailand
- Trial name
- NCT00005682
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Brain and Central Nervous System Tumors, Carcinoma of Unknown Primary
Topotecan in Treating Young Patients With Neoplastic Meningitis Due to Leukemia, Lymphoma, or Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as topotecan, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Brain and Central Nervous System Tumors, Carcinoma of Unknown Primary, Leukemia, Lymphoma
- Trial name
- NCT00112619
- Testing
- topotecan hydrochloride
- Where
- 11 sites in United States
- Volunteers
- 19 people
- Sponsor
- Pediatric Brain Tumor Consortium
Leukemia, Myelodysplastic Syndromes
Comparing Two Diets in Patients Undergoing HSCT or Remission Induction Chemo for Acute Leukemia and MDS (UF-BMT-LDND-101)
This is an open-label, two-arm, phase III non-inferiority trial to evaluate the safety of a liberalized hospital diet inclusive of fresh fruits and vegetables to a neutropenic diet in patients with prolonged neutropenia.
- Trial name
- NCT03016130
- Testing
- Diet
- Where
- United States
- Volunteers
- 217 people
- Sponsor
- University of Florida
Leukemia, Myeloid, Chronic-Phase
Imatinib Response in Patients With Chronic Myeloid Leukemia (CML) in Function of Abl Polymorphisms
The main objective of this study is to evaluate the existence of a relationship between the presence of certain abl polymorphisms (or haplotypes) upon CML diagnosis and the occurrence of primary resistance to the treatment of CML…
- Trial name
- abl LMC (NCT01650467)
- Where
- 3 sites in France
- Volunteers
- healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Acute Myocardial Infarction
Stem Cells in Myocardial Infarction
The purpose of this trial is to investigate the effect of treatment with granulocyte-colony stimulating factor (G-CSF) bone marrow stimulation on circulating stem cells' ability to develop new blood vessels in the myocardium…
- Trial name
- NCT00135928
- Testing
- Granulocyte Colony Stimulating Factor G-CSF (Neupogen®)
- Where
- Denmark
- Volunteers
- 78 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Chronic Myeloid Leukemia
TKI and Interferon Alpha Evaluation Initiated by the German Chronic Myeloid Leukemia Study Group - the TIGER Study
Advances in Chronic Myeloid Leukemia (CML) therapy led to an expected survival prolongation of > 20 years after diagnosis. So far, discontinuation of tyrosine kinase inhibitors led to recurrence of disease in the majority of…
- Trial name
- TIGER (NCT01657604)
- Testing
- Peginterferon α2b, Nilotinib
- Where
- 112 sites in Czechia, Germany and 1 more
- Volunteers
- 717 people
- Sponsor
- University of Jena
Fanconi Anemia
Long-Term Follow-up: Phase I/II Clinical Study to Evaluate the Safety and Efficacy of the Infusion of RP-L102
Long-Term Follow-up: Phase I/II clinical study to evaluate the safety and efficacy of the infusion of RP-L102
- Trial name
- NCT07527975
- Testing
- RP-L102
- Where
- 3 sites in United States, Spain and 1 more
- Volunteers
- 14 people
- Sponsor
- Rocket Pharmaceuticals Inc.
Myelofibrosis
Study of the JAK Inhibitor Ruxolitinib Administered Orally to Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF)
This is a Phase IB, open-label, dose-finding study of the JAK 1 and 2 inhibitor ruxolitinib in patients with myelofibrosis (MF).
- Trial name
- NCT01317875
- Testing
- Ruxolitinib
- Where
- 18 sites in United States, Austria and 6 more
- Volunteers
- 69 people
- Sponsor
- Incyte Corporation
Chronic Myelomonocytic Leukemia
Lenalidomide in Patients With Chronic Myelomonocytic Leukemia
In a phase I study the investigators plan to investigate safety and toxicity of lenalidomide in patients with Chronic Myelomonocytic Leukemia (CMML). A phase II study will be started once an optimal dose has been found.
- Trial name
- NCT01368757
- Testing
- Revlimid
- Where
- 10 sites in Austria
- Volunteers
- 30 people
- Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
Acute Myocardial Infarction
MYSTAR-5-YEAR: Long-term Follow-up of Patients With Ischemic Heart Disease Treated With Cell Therapy
The MYSTAR-5-YEAR study controls the patients 5 years after treatment with combined (intramyocardial and intracoronary) delivery of autologous BM-MNCs.
- Trial name
- MYSTAR-5-YEAR (NCT01395212)
- Where
- Austria
- Volunteers
- 60 people
- Sponsor
- Medical University of Vienna
Cartilage Injury, OA Knee
Tissue Engineered Cartilage to Repairing Articular Cartilage Defects
The joint cartilage constructed by combining bone marrow mesenchymal stem cells with three-dimensional materials has achieved the goal of repairing joint cartilage.
- Trial name
- NCT07094100
- Testing
- Tissue engineered cartilage
- Where
- China
- Volunteers
- 30 people
- Sponsor
- The First Affiliated Hospital of Xinxiang Medical College
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia
This phase I/II studies the side effects and best dose of natural killer cells before and after donor stem cell transplant and to see how well they work in treating patients with acute myeloid leukemia, myelodysplastic syndrome…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia With Gene Mutations, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Trial name
- NCT01904136
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Bone Marrow Transplantation, Cyclophosphamide
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- M.D. Anderson Cancer Center
Leukemia
Idarubicin and High-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia
RATIONALE: Drugs used in chemotherapy, such as idarubicin and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00528398
- Testing
- cytarabine, idarubicin
- Where
- 2 sites in United States
- Volunteers
- 111 people
- Sponsor
- City of Hope Medical Center
Cytopenia, MDS
Replacing Bone Marrow Diagnostics With Peripheral Blood Analysis in Cytopenia Patients
This observational, multi-center study aims to collect data in order to develop a novel, minimally invasive diagnostic tool for MDS based on peripheral blood profiling of circulating hematopoietic stem and progenitor cells…
- Trial name
- NCT07081087
- Testing
- PERIBLOOD-MDS
- Where
- 2 sites in United States
- Volunteers
- 1,500 people
- Sponsor
- Weizmann Institute of Science
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Study of Safety and Efficacy of MY008211A in in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
The main purpose of this study is to evaluate the efficacy of MY008211A in adult patients with PNH, showing signs of active hemolysis.
- Trial name
- NCT06134414
- Testing
- MY008211A tablets
- Volunteers
- 40 people
- Sponsor
- Wuhan Createrna Science and Technology Co., Ltd
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.